Generic Bynfezia Pen Availability
Last updated on May 7, 2025.
Bynfezia Pen is a brand name of octreotide, approved by the FDA in the following formulation(s):
BYNFEZIA PEN (octreotide acetate - solution;subcutaneous)
-
Manufacturer: SUN PHARM
Approval date: September 27, 2024
Strength(s): EQ 7MG BASE/2.8ML (EQ 2.5MG BASE/ML) [RLD]
Is there a generic version of Bynfezia Pen available?
No. There is currently no therapeutically equivalent version of Bynfezia Pen available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Bynfezia Pen. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Octreotide injection
Patent 10,342,850
Issued: July 9, 2019
Inventor(s): Rana Amar & Thummar Rakesh & Agrawal Sudeep & Bhowmick Subhas Balaram & Thennati Rajamannar
Assignee(s): SUN PHARMACEUTICAL INDUSTRIES LIMITEDThe present invention relates to a sterile solution comprising: octreotide in the form of a pharmaceutically acceptable salt, present at a concentration equivalent to 2.0 mg/ml to 2.5 mg/ml of octreotide base, and at least one preservative in a pharmaceutically acceptable vehicle, wherein the sterile solution is present in an injection device.
Patent expiration dates:
- May 15, 2038✓
- May 15, 2038
-
Method of injecting octreotide acetate into the body
Patent 11,052,196
Issued: July 6, 2021
Inventor(s): Patil; Satyashodhan Babasaheb et al.
Assignee(s): SUN PHARMACEUTICAL INDUSTRIES LIMITED (Mumbai, IN)A method of providing and/or injecting octreotide acetate to a subject in need thereof includes storing the octreotide acetate in a cartridge of a multi-use multi-dose injector provided with a variable dose setter and actuator. The injector includes a needle configured for subcutaneous administration of the octreotide acetate, the octreotide acetate having a concentration of 2,500 μg/mL. The method further includes providing, on the injector, a plurality of indicia only at prescribed doses of 50 μg, 100 μg, 150 μg and 200 μg settable via the dose setter without indicia between said prescribed doses; and permitting setting of a dose of the octreotide acetate by rotation of the variable dose setter, wherein the injector is configured to provide at least one audible feedback during the rotation.
Patent expiration dates:
- November 3, 2040✓
- November 3, 2040✓
- November 3, 2040✓
- November 3, 2040
-
Method of injecting octreotide acetate into the body
Patent 11,246,991
Issued: February 15, 2022
Inventor(s): Patil; Satyashodhan Babasaheb et al.
Assignee(s): SUN PHARMACEUTICAL INDUSTRIES LIMITED (Mumbai, IN)A method of providing and/or injecting octreotide acetate to a subject in need thereof includes storing the octreotide acetate in a cartridge of a multi-use multi-dose injector provided with a variable dose setter and actuator. The injector includes a needle configured for subcutaneous administration of the octreotide acetate, the octreotide acetate having a concentration of 2,500 μg/mL. The method further includes providing, on the injector, a plurality of indicia only at prescribed doses of 50 μg, 100 μg, 150 μg and 200 μg settable via the dose setter without indicia between said prescribed doses; and permitting setting of a dose of the octreotide acetate by rotation of the variable dose setter, wherein the injector is configured to provide at least one audible feedback during the rotation.
Patent expiration dates:
- November 3, 2040✓
- November 3, 2040✓
- November 3, 2040✓
- November 3, 2040
-
Method of injecting octreotide acetate into the body
Patent 11,534,553
Issued: December 27, 2022
Inventor(s): Patil; Satyashodhan Babasaheb et al.
Assignee(s): SUN PHARMACEUTICAL INDUSTRIES LIMITED (Maharashtra, IN)A method of providing and/or injecting octreotide acetate to a subject in need thereof includes storing the octreotide acetate in a cartridge of a multi-use multi-dose injector provided with a variable dose setter and actuator. The injector includes a needle configured for subcutaneous administration of the octreotide acetate, the octreotide acetate having a concentration of 2,500 μg/mL. The method further includes providing, on the injector, a plurality of indicia only at prescribed doses of 50 μg, 100 μg, 150 μg and 200 μg settable via the dose setter without indicia between said prescribed doses; and permitting setting of a dose of the octreotide acetate by rotation of the variable dose setter, wherein the injector is configured to provide at least one audible feedback during the rotation.
Patent expiration dates:
- November 3, 2040✓
- November 3, 2040✓
- November 3, 2040✓
- November 3, 2040
More about Bynfezia Pen (octreotide)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Drug images
- Latest FDA alerts (1)
- Side effects
- Dosage information
- During pregnancy
- Drug class: somatostatin and somatostatin analogs
- Breastfeeding
- En español
Patient resources
Other brands
Sandostatin, Sandostatin LAR Depot, Mycapssa
Professional resources
Other brands
Related treatment guides
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
